Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Clinical trial NCT02913261 · COMPLETED
Trial details
- NCT number
- NCT02913261
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-10
- Primary completion
- 2019-06-24
- Enrollment
- 310
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.